Secukinumab: A Review in Ankylosing Spondylitis

Drugs
Hannah A Blair

Abstract

Secukinumab (Cosentyx®), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and symptoms of AS versus placebo in three of four phase III trials. The benefits of secukinumab were generally seen regardless of whether patients had or had not received previous tumour necrosis factor (TNF) inhibitor therapy, and were sustained during longer-term (up to 5 years) treatment. Secukinumab was also associated with improvements in spinal mobility, physical function, health-related quality of life and work productivity in some of the trials. In MEASURE 1, secukinumab reduced inflammation in the sacroiliac joint, and slowed radiographic progression. Secukinumab was generally well tolerated during up to 5 years' treatment; the most commonly reported adverse event was nasopharyngitis. In the minority of patients who developed anti-drug antibodies (ADAs), ADAs did not decrease efficacy or increase adverse events. In conclusion, secukinumab is an effective therapy for TNF inhibitor-naive patients with active AS, and provides a useful tr...Continue Reading

References

Mar 1, 1983·Clinical Rheumatology·M Sadowska-WróblewskaT Wróblewska
Apr 24, 2007·Lancet·Jürgen Braun, Joachim Sieper
Jul 24, 2015·American Journal of Clinical Dermatology·Karly P Garnock-Jones
Dec 25, 2015·The New England Journal of Medicine·Dominique BaetenUNKNOWN MEASURE 2 Study Group
Jun 4, 2016·Drugs·Hannah A Blair, Sohita Dhillon
Jun 15, 2016·Drugs·Matt Shirley, Lesley J Scott
Jan 15, 2017·Annals of the Rheumatic Diseases·Désirée van der HeijdeJürgen Braun
Mar 21, 2017·Mediators of Inflammation·Taku KuwabaraTerutaka Kakiuchi
Apr 20, 2018·Mediators of Inflammation·I-Tsu Chyuan, Ji-Yih Chen
Sep 11, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·A V SearsA E Pink
Nov 27, 2018·Journal of Medical Economics·Timo PurmonenKari Puolakka

❮ Previous
Next ❯

Citations

May 6, 2020·Therapeutics and Clinical Risk Management·Maurizio BenucciFabrizio Cantini
Apr 23, 2020·Mediators of Inflammation·Stefano GentileschiLuca Cantarini
Jul 9, 2020·Therapeutic Advances in Musculoskeletal Disease·Mariagrazia LorenzinRoberta Ramonda
Jul 31, 2020·Expert Review of Clinical Immunology·Jin-Xian HuangJames Cheng-Chung Wei
Mar 5, 2020·Therapeutic Advances in Drug Safety·Senol Kobak
Oct 31, 2020·Indian Journal of Ophthalmology·Padmamalini MahendradasBhujang K Shetty
Jan 26, 2021·Therapeutic Advances in Musculoskeletal Disease·Bon San Koo, Tae-Hwan Kim
Mar 5, 2021·Drugs·Hannah A Blair
May 28, 2021·Scientific Reports·Xiaohua XueRobin L Thurmond

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02896127

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here